Posts Tagged ‘CK Science’

CK Science Salary Survey 2013

Friday, February 15th, 2013

Your chance to complete the 2013 CK Science Salary Survey is almost over.

Science jobsThe science salary survey will be closing at the end of February so this is the last chance you will have to  take part. It takes only 5 minutes to complete, and your participation will help us understand what the 2012 science salary brackets were. The results of this survey will be published and will help you with your job and salary expectations for 2013.

Click on the link below to complete the CK Science Salary Survey

https://www.surveymonkey.com/s/cksciencesalarysurvey

 Are you are currently looking for a job within the Science industry?

Click here to view all our science jobs

Science jobs uk   Science jobs UK

 

Cambridge scientists cure paralysed dogs using nose cells

Monday, November 19th, 2012

As reported by Sky News, scientists at Cambridge University used nose cells to help dogs with severe spinal injuries to walk again.

Scientists found that the dogs’ paralysis could be helped by fixing breaks in the spinal cord using olfactory ensheathing cells (OECs) taken from their noses. These cells support nerve fibre growth that maintains a communication pathway between the nose and the brain.

A random controlled trial was conducted by scientists studying 34 pet dogs who had suffered spinal injuries as a result of previous accidents and back problems (no dogs were harmed deliberately to aid the research).

One group of dogs (23 dogs in total) had the OEC cells injected into the injury site, whilst the other group only had the liquid in which the cells were suspended injected. Those dogs which had been injected with the OEC cells showed significant improvement and were able to walk on the treadmill with the support of a harness.

The scientist believe that the transplanted OEC cells regenerated nerve fibres across the damaged region of the spinal cord, enabling the dogs to regain the use of their hind legs and coordinate movement with their front limbs.

Professor Robin Franklin, one of the study leaders from Cambridge University, said: “Our findings are extremely exciting because they show for the first time that transplanting these types of cell into a severely damaged spinal cord can bring about significant improvement.”

The findings could provide hope for  humans suffering for paralysis, however Prof Franklin warns the treatment is likely to only restore “at least a small amount” of movement in affected limbs. It is expected that the procedure will need to be used as part of a combination of treatments, alongside drug and physical therapies.

Prof Geoffrey Raisman, chair of Neural Regeneration at University College London said: “This is not a cure for spinal cord injury in humans – that could still be a long way off.  But this is the most encouraging advance for some years and is a significant step on the road towards it.”

The study was funded by the Medical Research Council and was published in the neurology journal, Brain. The research was a collaboration between the Medical Research Council’s Regenerative Medical Centre and Cambridge University Veterinary School.

 

Are you looking for a job in science?Click here to search our science jobs online now >

 

 

Cambridge scientists cure paralysed dogs using nose cells   Cambridge scientists cure paralysed dogs using nose cells   Cambridge scientists cure paralysed dogs using nose cells   Cambridge scientists cure paralysed dogs using nose cells

Glasgow scientists receive £4m to develop ‘designer bacteria’

Friday, November 16th, 2012

As reported by Pharma Express, scientists at the University of Glasgow have received £4m from the UK Government to help them develop ‘designer bacteria’.

The Department for Business, Innovation and Skills has distributed funds through the Biotechnology and Biological Sciences Research Council with the overall aim of making the UK a world leader in research and application of synthetic biology.

The cash boost will be invested to help scientists and researchers in the Institute of Molecular, System and Cell Biology to develop tools for the production of useful strains of micro-organisms. The Glasgow scientists will use a family of enzymes called recombinases which act as molecular ‘scissors and glue’ for DNA. These will allow the researchers to cut the strands at precisely defined positions and ‘paste’ a new sequence into the gap. The researchers will also use the technology to ‘teach’ cells to count and keep a record of the number they have counted up to in their DNA.

The £4m for the project, which is being led by Prof Stark and his colleagues Dr Sean Colloms and Dr Susan Rosser, will also fund researchers at Aberdeen, York and Nottingham Universities.

David Willetts, Minister for Universities and Science, said, “Synthetic biology could provide solutions to the global challenges we face and offers significant growth opportunities in a range of important sectors from health to energy. However, the commercialisation of basic science is largely untapped. This investment will help to ensure that academics and industry can realise its full potential.”

 

Are you looking for a job in science? Click here to search our science jobs online now.

 

Glasgow scientists receive £4m to develop ‘designer bacteria’   Glasgow scientists receive £4m to develop ‘designer bacteria’   Glasgow scientists receive £4m to develop ‘designer bacteria’   Glasgow scientists receive £4m to develop ‘designer bacteria’

 

A new-state-of-the-art Science park will bring 2,000 jobs to Wiltshire

Thursday, October 25th, 2012

ThA new-state-of-the-art Science park will bring 2,000 jobs to Wiltshiree Swindon Advertiser has reported that a new state-of-the-art science park will be developed at Porton in Wiltshire creating more than 2,000 jobs over a 10-year-period and bringing national and international investment into the area.

Wiltshire Council and a joint development company, comprising Trebor Developments LLP and Wrenbridge Land Limited, will develop the science park. The successfully bided  for £10m funding from the Department of Business, Innovation and Skills (BIS). This will help kick-start the first phase of the science park project, creating the infrastructure for the planned 355,000 sq ft science park and a new 23,000 sq ft innovation centre

This new science park will  provide facilities for science- and research-based industries and could attract £70m of private sector investment over the next 10 years.

 

Are you looking for a new science based role?

Click here to see our latest science jobs

Pharmaceutical Export Sales Manager – Home Working / London

Monday, October 22nd, 2012

Jason Johal at CK Science is currently recruiting for a Pharmaceutical Export Sales Manager for an amazing role with an MHRA licensed pharmaceutical manufacturing organisation based in London on a full time, permanent basis.

Responsibilities:

This newly formed Pharmaceutical Export Sales Manager role offers a blank canvas in regards to where you can take it and what you can achieve. It would be ideal for a person with an “explorer” personality and for someone looking for a role with autonomy, challenges and happy to travel globally.

The company are looking for someone that can grow their export business by developing strategies, using current/new contacts within Europe, the Middle East and by utilising their regulatory and pharmaceutical knowledge.

As an Export Sales Manager you will:

  • Develop the overall sales strategy plan for export sales
  • Plan and manage overseas sales through direct customers, distributors and other relevant sales outlets
  • Identify potential partners / distributors / countries for export opportunities
  • Manage export accounts to achieve sales targets, liaising closely with the Sales & Marketing Director, to develop and maximise all sales opportunities
  • Negotiate and manage contracts for sales/ distribution as required to enable effective trading, operations and customer relations
  • Develop knowledge and understanding of local requirements for pharmaceuticals, medical devices and “specials”.
  • Develop export programmes to promote new products and actively support all product promotions to customers
  • Liaise with customers services to process orders, enquiries, sample requests, catalogue requests and offer quotations
  • Deal with customer complaints in a professional and helpful manner
  • Organise and attend customer visits and represent company at trade shows as part of an agreed plan
  • Manage the movement of products in and out of the country in accordance with organisational policy and procedure, and to comply with relevant local, country and international law and process
  • Manage the necessary administration and documentation for the efficient, cost-effective and lawful execution of all export activities. Liaising with regulatory, finance and other departments as required

Qualifications:

The successful applicant for this Export Sales Manager will have the following qualifications, skills & experiences:

  • An experienced Pharmaceutical export sales professional
  • An understanding and experience of setting up distributors in overseas markets
  • Knowledge or experience of the ophthalmology (highly advantageous not essential)
  • The ability to travel for prolonged periods of time
  • A working knowledge of regulatory issues overseas
  • The ability to develop and execute coherent business strategies and plans
  • A detailed understanding of Pharmaceutical industry
  • Be self motivated (minimum supervision required)
  • Strong Communication skills (Verbal and Written)
  • A second European language would be an advantage but is not essential

Benefits:

This Pharmaceutical Export Sales Manager role is a really exciting job for a pharmaceutical sales professional as it offers the opportunity to establish and then develop your own strategies and the freedom to build your career in the direction you want to go.  If successful, you will be joining a Specials Manufacturer with a growing portfolio of branded licensed products coupled with a world renowned reputation. In return there is an attractive salary, coupled with excellent benefits and travel opportunities.

Jason Johal - Pharmaceutical Recruitment

Please contact Jason for more details.

How to apply:

Apply online:

To apply for this Export Sales Manager position, contact Jason Johal via email: jjohal@ckscience.co.uk or 01438 723 500. Please quote reference ST25513 in all correspondence.

 

Are you looking for a new job in the pharmaceutical  industry?

Click here to see our latest pharmaceutical jobs?

Pharmaceutical Export Sales Manager

 

 

 

 

GSK invest 10 million euros at their facility in Sligo, Ireland

Thursday, October 18th, 2012

Pharmatimes have reported that GlaxoSmithKline has decided to keep open its facility in Sligo Ireland and will instead invest 10 million euros into the plant.

GSK acquired the facility in Sligo when GSK bought the dermatology specialist Stiefel Laboratories for up to $3.6 billion in 2009.

There will be some jobs cuts at the plant over the next two years, which currently employs 180 people, with a “gradual” reduction to 120. However, GlaxoSmthKline estimated there would be an additional 50 jobs added in 2014 as the plant improved skills and capacity.

 

If you are looking for a new job in science why not look at our current science based vacancies?

Click here to see our latest jobs in the science industry

UK stem cell pioneer shares Nobel Prize in Medicine

Monday, October 8th, 2012

The BBC has reported that two pioneers of stem cell research have shared the Nobel prize for medicine and/ or physiology

John Gurdon from the UK and Shinya Yamanaka from Japan have been jointly awarded the prize for their work in transforming specialised cells into stem cells, which can become any other type of cell in the body. It is hoped the techniques discovered will revolutionise medicine by using a sample of a person’s skin to create stem cells.

Prof Anthony Hollander, the head of cellular and molecular medicine at the University of Bristol, said: “This joint Nobel Prize traces and celebrates the wonderful scientific journey from John Gurdon’s pioneering early work to the sensational discovery of somatic cell reprogramming by Shinya Yamanaka. It’s fantastic news for stem cell research.”

The prize was awarded this morning at the Karolinska Institute in Sweden, and is the most coveted award in medical science. The Nobel committee said these winners  had “revolutionised” science

 

If you are looking for a new job in science why not look at our current science based vacancies?

Click here to see our latest jobs in the science industry

 

Offshore Energy Network to Create Jobs

Friday, October 5th, 2012

Renewable energy group Norstec has been back by the government with the aim of creating thousands of jobs in the North East, reports the Northern Echo.

Norstec is a group of several companies in the North East, including the Deep Ocean Group and JDR Cables. The companies met to discuss how to make the best use of the potential of the sector which is expected to create around 1,000 jobs in the area. This is a major boost to offshore wind power as it shows a concerted effort by the government to back the sector.

The Prime Minister has stated that “close collaboration between industry and government will be critical to making this happen.” The Climate Change Secretary then added “The offshore wind industry represents a massive growth opportunity for the UK and our neighbours around the northern seas, bringing jobs and reenergising once thriving industrial heartlands on the east coast and beyond.”

Looking for a job in the renewable energy sector? Start by clicking here

Allergans Botox receives UK approval for treatment of MS/spinal injury

Tuesday, October 2nd, 2012

CK Science - Scientific Recruitment AgencyPharmaTimes have reported that Allergan’s Botox is now licensed in the UK for patients who have continence issues because of multiple sclerosis or a spinal injury.

The Medicines and Healthcare products Regulatory Agency has give Allergan permission to use Botox (botulinum toxin type A) for managing urinary incontinence caused by neurogenic detrusor overactivity due to subcervical spinal cord injury or multiple sclerosis (MS),

Professor Christopher Chapple, Urology Department, Royal Hallamshire Hospital, Sheffield NHS Trust and a key investigator in the neurogenic detrusor overactivity registration trials, has welcomed the new license, noting that “being able to better control and manage bladder function can be life-changing for patients”.

 

If you are looking for a new job in science why not look at our current science based vacancies?

Click here to see our latest jobs in the science industry

UCB launches its new biotechnology facility in Belgium

Tuesday, September 18th, 2012

PharmaTimes has reported that UCB has launched its 65 million euro pilot biotechnology plant in Belgium.

The new facility is located at its Braine-l’Alleud site and will employ 100 employees. This new facility will produce cell culture-based therapeutic proteins that are dedicated to accelerating the availability of new drugs for severe diseases with a focus on the research and clinical trial phases

This new facility is designed enable UCB to improve its biological medicines.

Chief executive Roch Doliveux said that “today, 33% of drugs for human use worldwide are of biotechnological origin and represent more than half of UCB’s current R&D pipeline”. He added that “with this bio pilot plant, we will more rapidly initiate clinical studies of new antibody-based therapeutics”.

 

Are you looking for a new science based role?

Click here to see our latest science jobs

Search for a job

Advanced search

20 years Download the CK Science iPhone App

Subscribe to our newsletter

Preview
Powered by FeedBlitz


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close